Clinical Trials

450 enrolled

Genitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07174336 2026-05-22

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07492641 2026-05-22

KANDELA-302

1,056 enrolled

HR+/HER2- Breast Cancer

NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

1,050 enrolled

Breast Neoplasm Female

NCT04546009 2026-05-19

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

992 enrolled

Breast Neoplasms

NCT06760637 2026-05-19

FourLight-3

1,035 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-05-18

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

1,180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06380751 2026-05-15

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT02297438 2026-05-14

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

340 enrolled 33 charts

Breast Neoplasms, Neoplasm Metastasis

NCT06377852 2026-05-13

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

500 enrolled

Breast Neoplasms

NCT06065748 2026-05-05

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT03784014 2026-04-29

MULTISARC

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT04964934 2026-04-21

SERENA-6

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT03820830 2026-04-09

POLAR

405 enrolled

Breast Cancer Recurrent

NCT02947685 2026-02-12

PATINA

518 enrolled 15 charts

Breast Neoplasms

NCT02513394 2026-02-10

PALLAS

5,796 enrolled 14 charts

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

701 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05909397 2026-02-10

VERITAC-3

59 enrolled

Breast Neoplasms

NCT03079011 2025-11-18

PADA-1

1,017 enrolled

Breast Neoplasms

NCT04711252 2025-10-14

SERENA-4

1,370 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07061717 2025-07-11

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

474 enrolled

Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer

NCT05207709 2025-04-29

HARMONIA

456 enrolled

Breast Neoplasms

NCT01740427 2024-11-14

PALOMA-2

666 enrolled 22 charts

Breast Neoplasms, Neoplasm Metastasis

NCT02028507 2024-09-25

PEARL

693 enrolled 40 charts

Breast Neoplasms

NCT01942135 2024-04-04

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

521 enrolled 31 charts

Breast Neoplasms

NCT03423199 2024-03-22

PATHWAY

Phase 3 Unknown

180 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT01864746 2023-12-12

PENELOPE-B

1,250 enrolled 12 charts

Breast Neoplasms

NCT03447132 2023-03-10

SAFIA

354 enrolled

Breast Neoplasms

NCT03969121 2023-03-10

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

141 enrolled

Breast Neoplasms

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

120 enrolled

HER2+ Breast Cancer

NCT02600923 2022-01-20

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

131 enrolled 12 charts

Breast Neoplasms

NCT04047758 2021-07-20

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Phase 3 Unknown

420 enrolled